🔗 Visit the ClinicalTrials.gov page for NCT02152943
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? | J Exp Clin Cancer Res | 2016 | 0.78 |
| 2 | Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. | Ther Adv Med Oncol | 2016 | 0.75 |